# USING FORTILIN INHIBITORS TO BLOCK ATHEROSCLEROSIS

> **NIH NIH R01** · UNIVERSITY OF WASHINGTON · 2020 · $542,463

## Abstract

Project Summary
The main goal of this grant proposal titled “Using Fortilin Inhibitors to Block Atherosclerosis” is to
generate small molecular weight inhibitors of fortilin (named FISCs: fortilin inhibiting small molecular
weight compounds) and test the hypothesis that FISCs protect against atherosclerosis by silencing
fortilin in macrophages (MΦ), inducing MΦ apoptosis, and polarizing MΦ to the anti-inflammatory M2
phenotype. By 2025, the worldwide death due to atherosclerosis and associated complications is projected to
surpass that of every major disease, including cancer, infection, and trauma. The total cost of atherosclerosis-
related diseases in the U.S. alone is estimated to be $286 billion annually. After statins, there is no break-
through strategy in the pipeline to contain this deadly and global disease. Statins alone have not been able to
eliminate atherosclerosis. There is an urgent need to identify other molecular targets of atherosclerosis and
devise strategies to attack them. Successful strategies would be highly significant and advance the field of
atherosclerosis therapeutics. Our laboratory has studied fortilin, a 172-amino acid multi-functional protein, for
the last 15 years. Using fortilin-deficient mice placed on the hypercholesterolemia genetic background, we
discovered that fortilin promotes atherosclerosis. Next, we screened 14,400 drug-like small molecular weight
(SMW) compounds using biochemical and cellular methods. After primary, secondary, and tertiary screening,
we identified the three most promising compounds (“hits”) and named them FISC11C09, FISC172E05, and
FISC107B10. Preliminary studies revealed that these three compounds are safe and possess many positive drug-
like attributes. The project is innovative because SMW inhibitors of fortilin have never been identified and we
propose to use them to halt atherosclerosis. However, these compounds are not yet potent enough to be used
in humans. Having assembled a team with expertise in fortilin, structural biology and computational drug
design, medicinal chemistry, pharmacology and toxicology, and atherosclerosis, we here propose to first modify
structures of the three FISC compounds to generate highly potent and safe lead compounds (FISCLEADs)(Aim
1). We will test the FISCLEADs for their pharmacokinetics and toxicology attributes and modify them further as
needed to generate the final compounds (FISCBESTs) that are appropriate for use in whole animals (Aim 2).
Having developed and validated the MΦ-specific compound delivery system, we will finally administer
FISCBESTs to the hypercholesterolemic Ldlr-/-Apobec1-/- mice systemically as well as in a MΦ-specific fashion to
test the hypothesis that fortilin inhibition ameliorates the development and progression of atherosclerosis (Aim
3). Upon completion of the project, we expect to have generated and validated SMW fortilin inhibitors
that are ready for testing in clinical trials.

## Key facts

- **NIH application ID:** 10104076
- **Project number:** 7R01HL138992-04
- **Recipient organization:** UNIVERSITY OF WASHINGTON
- **Principal Investigator:** Ken Fujise
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $542,463
- **Award type:** 7
- **Project period:** 2017-07-01 → 2023-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10104076

## Citation

> US National Institutes of Health, RePORTER application 10104076, USING FORTILIN INHIBITORS TO BLOCK ATHEROSCLEROSIS (7R01HL138992-04). Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/grant/nih/10104076. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*